skezan, you asked abut the data/results from the Long Covid trial. I asked a friend the same question and they reminded me that an article was published in Medicalxpress.

https://medicalxpress.com/news/2022-04-cases-...mmune.html

Not a lot of detail, but Dr. Yang did write this:

Quote:

---

The researchers originally thought that blocking CCR5 with the antibody would dampen the activity of an overactive immune system after COVID-19 infection.

"But we found just the opposite," Yang said. "Patients who improved were those who started with low CCR5 on their T cells, suggesting their immune system was less active than normal, and levels of CCR5 actually increased in people who improved. This leads to the new hypothesis that long COVID in some persons is related to the immune system being suppressed and not hyperactive, and that while blocking its activity, the antibody can stabilize CCR5 expression on the cell surface leading to upregulation of other immune receptors or functions."

---

More details were given in this article in "Clinical Infectious Diseases".

https://academic.oup.com/cid/article/75/7/123...chresult=1

I noticed that the results were never posted on the ClinicalTrials website.

https://clinicaltrials.gov/study/NCT04678830?...ab=results

I do hope that CYDY will partner with someone who can pursue LC trials.